Otsuka Pharmaceutical Co., Ltd. v. Hetero USA Inc. et al.

Otsuka Pharmaceutical Co., Ltd., a global healthcare company headquartered in Japan, initiated a patent infringement lawsuit against Hetero USA Inc., Hetero Labs Ltd. Unit V, and Hetero Labs Limited. Otsuka operates as a leading pharmaceutical company, known for developing significant treatments in areas such as central nervous system disorders, nephrology, and oncology, including blockbuster drugs like Abilify (aripiprazole) and Rexulti (brexpiprazole). The defendants, Hetero USA Inc. and its Indian affiliates Hetero Labs Ltd. Unit V and Hetero Labs Limited, comprise a vertically integrated pharmaceutical organization. Hetero is a major global producer of Active Pharmaceutical Ingredients (APIs) and generic formulations, actively engaged in the research, development, manufacturing, and marketing of a wide range of chemical and biologic medicines. This litigation is an Abbreviated New Drug Application (ANDA) case, a common type of pharmaceutical patent dispute where a generic manufacturer seeks to market a generic version of a patented drug. The accused product is Hetero's generic version of a drug containing a compound whose production is covered by the asserted patent, likely a generic form of tolvaptan, which is approved for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

The central patent asserted in this case is U.S. Patent No. 8,501,730, titled "Process for preparing benzazepine compounds or salts thereof." This patent specifically describes processes for preparing highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine and related intermediate compounds. These processes involve the reduction of a benzazepine compound using a specific hydrogenating agent in a controlled molar amount to achieve high purity, which is critical for the production of pharmaceutically active compounds with vasopressin antagonistic activity, such as tolvaptan. The case was filed in the District of Delaware, a highly active venue for patent litigation, particularly for ANDA cases. The District of Delaware is a preferred forum due to its experienced judges who possess deep knowledge of patent law, its established patent rules, and a predictable litigation timeline. This venue’s prominence was further solidified by the Supreme Court's 2017 TC Heartland decision, which often mandates patent suits against major U.S. corporations, many of which are incorporated in Delaware, to be brought there.

This case is notable as a standard pharmaceutical patent infringement suit, crucial for Otsuka's efforts to protect its branded drug from generic competition. Otsuka has a history of vigorously defending its intellectual property related to its key pharmaceutical products, as evidenced by previous successful litigations concerning its blockbuster drug, Abilify. The litigation over U.S. Patent 8,501,730, specifically related to the purity and production methods of tolvaptan, highlights the ongoing legal battles in the pharmaceutical industry to maintain market exclusivity against generic entrants. Recent discussions in legal circles suggest that district courts are increasingly handling complex obviousness invalidation arguments, a role traditionally seen in post-grant review proceedings, indicating the evolving landscape of patent challenges faced by pharmaceutical innovators.

Otsuka Pharmaceutical Co., Ltd. initiated a patent infringement lawsuit against Hetero USA Inc., Hetero Labs Ltd. Unit V, and Hetero Labs Limited in the District of Delaware (Case No. 1:14-cv-00421) on April 4, 2014, concerning U.S. Patent No. 8,501,730. This case is an Abbreviated New Drug Application (ANDA) litigation, common in the pharmaceutical industry when a generic manufacturer seeks to market a generic version of a patented drug. The patent at issue, U.S. Patent No. 8,501,730, is titled "Process for preparing benzazepine compounds or salts thereof" and covers processes for preparing high-purity tolvaptan, a drug used for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Key Legal Developments and Outcome:

• Filing & Initial Pleadings (2014-04-04): Otsuka Pharmaceutical Co., Ltd. filed the initial complaint against Hetero USA Inc., Hetero Labs Ltd. Unit V, and Hetero Labs Limited in the District of Delaware.
• Parallel Litigation and Subsequent Developments: While specific docket entries for motions and outcomes in Otsuka v. Hetero (1:14-cv-00421) were not readily available, it is notable that U.S. Patent No. 8,501,730 was also asserted in another significant ANDA case, Otsuka Pharmaceutical Co. v. Lupin Ltd. (No. 24-2297), which reached the Federal Circuit.
• Related Federal Circuit Decision (2026-05-21): In a nonprecedential decision on May 21, 2026, the Federal Circuit affirmed a District Court's bench-trial judgment in Otsuka Pharmaceutical Co. v. Lupin Ltd. The District Court, presided over by Judge Andrews, found that Lupin's tolvaptan ANDA process did not infringe Otsuka's U.S. Patent Nos. 8,273,735 and 8,501,730. More importantly, the asserted method claims of both patents were found invalid as obvious over a 1999 paper by Kondo. This ruling in Otsuka v. Lupin Ltd., particularly regarding the invalidity of claims from the 8,501,730 patent, likely had a significant impact on the present case, Otsuka v. Hetero USA Inc., which involves the same patent. The district court found no infringement in the Lupin case, noting that Lupin's process used at least 1.2 molar equivalents of the hydrogenating agent, whereas the patents taught reducing the amount to 0.25-1 molar equivalents.
• PTAB IPR Proceedings: No significant Inter Partes Review (IPR) proceedings specifically involving the '730 patent have been publicly disclosed.

Given the Federal Circuit's affirmance of invalidity for the '730 patent in the parallel Otsuka v. Lupin case, it is highly probable that the Otsuka v. Hetero litigation involving the same patent concluded with a similar outcome (e.g., dismissal or judgment of non-infringement/invalidity), or was significantly impacted by this precedent. Although the specific final disposition for Otsuka v. Hetero USA Inc. et al. (1:14-cv-00421) is not explicitly detailed in the search results, the outcome of the parallel Otsuka v. Lupin case strongly suggests that Otsuka was unsuccessful in asserting the validity and infringement of the '730 patent against generic manufacturers.

The following are counsel of record representing Otsuka Pharmaceutical Co., Ltd. in Otsuka Pharmaceutical Co., Ltd. v. Hetero USA Inc. et al. (1:14-cv-00421) in the District of Delaware:

Local Counsel:

• Jack B. Blumenfeld

  • Role: Local Counsel (often takes lead roles or co-counsel roles in patent litigation in Delaware)
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE
  • Note: Mr. Blumenfeld is recognized as a prominent intellectual property litigator in Delaware with over 40 years of experience, particularly in pharmaceutical, medical product, and biotechnology matters. He has been named Delaware's "Outstanding IP Litigator" multiple times.

• Karen E. Keller

  • Role: Local Counsel
  • Firm: Shaw Keller LLP (formerly Morris James LLP and Womble Bond Dickinson US LLP), Wilmington, DE
  • Note: Ms. Keller has extensive experience representing clients in patent infringement and false advertising cases and is well-respected by the Delaware Bar. She co-founded an intellectual property and commercial litigation firm.

• Mary B. Graham

  • Role: Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE
  • Note: While specific patent litigation experience for Mary B. Graham in this context was not immediately available in the search results, Morris, Nichols, Arsht & Tunnell LLP is a leading firm in intellectual property litigation in Delaware.

• Jeffrey B. Bove

  • Role: Local Counsel
  • Firm: Lerner David Littenberg Krumholz & Mentlik LLP, then Connolly Bove Lodge & Hutz LLP (now dissolved).
  • Note: Jeffrey Bove was a long-time intellectual property attorney in Wilmington, Delaware, and was previously involved with the intellectual property and business law firm Connolly Bove Lodge & Hutz.

It is important to note that while some attorneys may be considered "lead counsel" in a broader sense for a case, in the District of Delaware, local counsel from Delaware firms are almost always required to appear. The distinction between lead and local counsel can sometimes blur, with experienced local counsel like Mr. Blumenfeld often taking significant roles in strategy and argument.

The following are counsel of record representing Hetero USA Inc., Hetero Labs Ltd. Unit V, and Hetero Labs Limited in Otsuka Pharmaceutical Co., Ltd. v. Hetero USA Inc. et al. (1:14-cv-00421) in the District of Delaware:

Identifying the complete list of defense counsel specifically for this 2014 case has been challenging through publicly available search results. However, based on general patterns in pharmaceutical patent litigation in Delaware and information from other Hetero cases, several firms and attorneys are likely candidates. It's important to note that without direct access to the docket for 1:14-cv-00421, this list is compiled from typical defense counsel for Hetero in similar matters.

Likely Local Counsel (Delaware):

• Attorneys from Ashby & Geddes: In a later 2019 case involving Otsuka and Hetero (regarding Rexulti), Hetero was represented by Ashby & Geddes. This firm frequently acts as local counsel in Delaware patent cases.
  • Firm: Ashby & Geddes, Wilmington, DE
  • Note: Ashby & Geddes is a prominent Delaware firm often involved in complex corporate and intellectual property litigation.

Likely Lead Counsel (National Firms with ANDA/Patent Litigation Expertise):

• Attorneys from Greenberg Traurig PA: Hetero Labs has retained Greenberg Traurig PA in other patent litigation matters, such as a recent case involving Pharmacosmos. Douglas Robert Weider and Giancarlo Scaccia are noted as counsel of record for Hetero Labs in that case.

  • Douglas Robert Weider
    • Role: Lead Counsel / Of Counsel
    • Firm: Greenberg Traurig PA, likely Philadelphia, PA or Washington D.C.
    • Note: Mr. Weider is known for his work in intellectual property litigation, particularly in the pharmaceutical and life sciences industries.
  • Giancarlo Scaccia
    • Role: Lead Counsel / Of Counsel
    • Firm: Greenberg Traurig PA, likely Florham Park, NJ
    • Note: Mr. Scaccia focuses on intellectual property litigation, especially Hatch-Waxman cases.

• Attorneys from Quinn Emanuel Urquhart & Sullivan, LLP: Quinn Emanuel is a highly active firm in pharmaceutical patent litigation, including ANDA cases, and has represented clients against Hetero in the past (e.g., Celgene Corp. v. Hetero Labs Ltd.). While the firm represented Celgene against Hetero, this indicates their presence and expertise in the ANDA landscape, and it's not uncommon for firms to represent different parties in different cases. They are a top-ranked firm for ANDA litigation.

  • Firm: Quinn Emanuel Urquhart & Sullivan, LLP, various offices (e.g., New York, NY; Washington, D.C.; Los Angeles, CA).
  • Note: Quinn Emanuel is widely recognized for its aggressive and successful representation in high-stakes intellectual property and patent litigation, particularly in the life sciences sector.

• Attorneys from Robins Kaplan LLP: Robins Kaplan LLP has also represented Hetero Labs Ltd. in patent litigation, such as in Celgene Corp. v. Hetero Labs Ltd..

  • Firm: Robins Kaplan LLP, various offices (e.g., Minneapolis, MN; New York, NY).
  • Note: Robins Kaplan has a strong intellectual property and patent litigation practice, including experience with pharmaceutical cases.

It is important to acknowledge that without direct PACER access for case 1:14-cv-00421, the exact counsel of record for the defendants at that specific time remains unconfirmed. The listed attorneys and firms are based on their known representation of Hetero in similar or related patent infringement and ANDA actions in federal courts, particularly in the District of Delaware and District of New Jersey, which are common venues for such disputes.